Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Study achieves primary endpoint of radiographic progression-free survival
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
Subscribe To Our Newsletter & Stay Updated
